- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00936702
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well carboplatin given together with paclitaxel and everolimus works in treating patients with previously untreated cancer of unknown primary.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Evaluate the response rate in patients with previously untreated cancer of unknown primary treated with the combination of carboplatin, paclitaxel, and everolimus.
Secondary
- Assess time to progression, overall survival, duration of response, and time to treatment failure in patients treated with this regimen.
- Determine adverse events of this regimen in these patients.
- Perform descriptive correlative studies to determine response of specific tumor types, identified by the Origin-FFPE test, to this regimen.
OUTLINE: This is a multicenter study.
Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Patients also receive oral everolimus once daily on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients' tumor tissue samples from the most recent biopsy are analyzed for correlative studies, including gene expression profiling by Origin-FFPE test.
After completion of study therapy, patients are followed up every 3 months until disease progression, and then every 6 months for up to 3 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Colorado
-
Fort Collins, Colorado, United States, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, United States, 80528
- Front Range Cancer Specialists
-
-
Connecticut
-
Hartford, Connecticut, United States, 06105
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
-
-
Illinois
-
Moline, Illinois, United States, 61265
-
Moline, Illinois, United States, 61265
- Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
-
-
Indiana
-
Elkhart, Indiana, United States, 46515
- Elkhart General Hospital
-
Elkhart, Indiana, United States, 46514-2098
- Elkhart Clinic, LLC
-
Elkhart, Indiana, United States, 46514
- Michiana Hematology-Oncology, PC - Elkhart
-
Indianapolis, Indiana, United States, 46237
- St. Francis Hospital Cancer Care Services
-
Kokomo, Indiana, United States, 46904
- Howard Community Hospital
-
La Porte, Indiana, United States, 46350
- Center for Cancer Therapy at LaPorte Hospital and Health Services
-
Mishawaka, Indiana, United States, 46545-1470
- Michiana Hematology-Oncology, PC - South Bend
-
Mishawaka, Indiana, United States, 46545-1470
- Saint Joseph Regional Medical Center
-
Plymouth, Indiana, United States, 46563
- Michiana Hematology Oncology PC - Plymouth
-
Richmond, Indiana, United States, 47374
- Reid Hospital & Health Care Services
-
South Bend, Indiana, United States, 46601
- Memorial Hospital of South Bend
-
South Bend, Indiana, United States, 46601
- CCOP - Northern Indiana CR Consortium
-
Westville, Indiana, United States, 46391
- Michiana Hematology Oncology PC - La Porte
-
-
Iowa
-
Ames, Iowa, United States, 50010
- McFarland Clinic, PC
-
Bettendorf, Iowa, United States, 52722
-
Cedar Rapids, Iowa, United States, 52403
- Cedar Rapids Oncology Associates
-
Cedar Rapids, Iowa, United States, 52403
- Mercy Regional Cancer Center at Mercy Medical Center
-
Clive, Iowa, United States, 50325
- Medical Oncology and Hematology Associates - West Des Moines
-
Des Moines, Iowa, United States, 50309
- CCOP - Iowa Oncology Research Association
-
Des Moines, Iowa, United States, 50309
- John Stoddard Cancer Center at Iowa Methodist Medical Center
-
Des Moines, Iowa, United States, 50309
- Medical Oncology and Hematology Associates at John Stoddard Cancer Center
-
Des Moines, Iowa, United States, 50314
- Medical Oncology and Hematology Associates at Mercy Cancer Center
-
Des Moines, Iowa, United States, 50314
- Mercy Cancer Center at Mercy Medical Center - Des Moines
-
Des Moines, Iowa, United States, 50316
- John Stoddard Cancer Center at Iowa Lutheran Hospital
-
Ottumwa, Iowa, United States, 52501
- McCreery Cancer Center at Ottumwa Regional
-
Sioux City, Iowa, United States, 51101
- Siouxland Hematology-Oncology Associates, LLP
-
Sioux City, Iowa, United States, 51102
- Mercy Medical Center - Sioux City
-
Sioux City, Iowa, United States, 51104
- St. Luke's Regional Medical Center
-
-
Kansas
-
Chanute, Kansas, United States, 66720
- Cancer Center of Kansas, PA - Chanute
-
Dodge City, Kansas, United States, 67801
- Cancer Center of Kansas, PA - Dodge City
-
El Dorado, Kansas, United States, 67042
- Cancer Center of Kansas, PA - El Dorado
-
Fort Scott, Kansas, United States, 66701
- Cancer Center of Kansas - Fort Scott
-
Independence, Kansas, United States, 67301
- Cancer Center of Kansas-Independence
-
Kingman, Kansas, United States, 67068
- Cancer Center of Kansas, PA - Kingman
-
Lawrence, Kansas, United States, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, United States, 67901
- Cancer Center of Kansas, PA - Liberal
-
Newton, Kansas, United States, 67114
- Cancer Center of Kansas, PA - Newton
-
Parsons, Kansas, United States, 67357
- Cancer Center of Kansas, PA - Parsons
-
Pratt, Kansas, United States, 67124
- Cancer Center of Kansas, PA - Pratt
-
Salina, Kansas, United States, 67401
- Cancer Center of Kansas, PA - Salina
-
Wellington, Kansas, United States, 67152
- Cancer Center of Kansas, PA - Wellington
-
Wichita, Kansas, United States, 67208
- Cancer Center of Kansas, PA - Medical Arts Tower
-
Wichita, Kansas, United States, 67214
- Cancer Center of Kansas, PA - Wichita
-
Wichita, Kansas, United States, 67214
- CCOP - Wichita
-
Wichita, Kansas, United States, 67214
- Via Christi Cancer Center at Via Christi Regional Medical Center
-
Wichita, Kansas, United States, 67208
- Associates in Womens Health, PA - North Review
-
Winfield, Kansas, United States, 67156
- Cancer Center of Kansas, PA - Winfield
-
-
Michigan
-
Adrian, Michigan, United States, 49221
- Hickman Cancer Center at Bixby Medical Center
-
Ann Arbor, Michigan, United States, 48106-0995
- Saint Joseph Mercy Cancer Center
-
Ann Arbor, Michigan, United States, 48106
- CCOP - Michigan Cancer Research Consortium
-
Battle Creek, Michigan, United States, 49017
- Battle Creek Health System Cancer Care Center
-
Dearborn, Michigan, United States, 48123-2500
- Oakwood Cancer Center at Oakwood Hospital and Medical Center
-
Escanaba, Michigan, United States, 49431
- Green Bay Oncology, Limited - Escanaba
-
Flint, Michigan, United States, 48503
- Hurley Medical Center
-
Flint, Michigan, United States, 48503
- Genesys Hurley Cancer Institute
-
Grand Rapids, Michigan, United States, 49503
- Butterworth Hospital at Spectrum Health
-
Grand Rapids, Michigan, United States, 49503
- CCOP - Grand Rapids
-
Grand Rapids, Michigan, United States, 49503
- Lacks Cancer Center at Saint Mary's Health Care
-
Grosse Pointe Woods, Michigan, United States, 48236
- Van Elslander Cancer Center at St. John Hospital and Medical Center
-
Iron Mountain, Michigan, United States, 49801
- Dickinson County Healthcare System
-
Jackson, Michigan, United States, 49201
- Foote Memorial Hospital
-
Lansing, Michigan, United States, 48912-1811
- Sparrow Regional Cancer Center
-
Livonia, Michigan, United States, 48154
- St. Mary Mercy Hospital
-
Monroe, Michigan, United States, 48162
- Community Cancer Center of Monroe
-
Monroe, Michigan, United States, 48162
- Mercy Memorial Hospital - Monroe
-
Muskegon, Michigan, United States, 49444
- Mercy General Health Partners
-
Pontiac, Michigan, United States, 48341-2985
- St. Joseph Mercy Oakland
-
Port Huron, Michigan, United States, 48060
- Mercy Regional Cancer Center at Mercy Hospital
-
Reed City, Michigan, United States, 49677
- Spectrum Health Reed City Hospital
-
Saginaw, Michigan, United States, 48601
- Seton Cancer Institute at Saint Mary's - Saginaw
-
Saint Joseph, Michigan, United States, 49085
- Lakeside Cancer Specialists, PLLC
-
Saint Joseph, Michigan, United States, 49085
- Lakeland Regional Cancer Care Center - St. Joseph
-
Traverse City, Michigan, United States, 49684
- Munson Medical Center
-
Warren, Michigan, United States, 48093
- St. John Macomb Hospital
-
-
Minnesota
-
Bemidji, Minnesota, United States, 56601
- MeritCare Bemidji
-
Duluth, Minnesota, United States, 55805
- CCOP - Duluth
-
Duluth, Minnesota, United States, 55805
- Miller - Dwan Medical Center
-
Duluth, Minnesota, United States, 55805-1983
- Essentia Health - Duluth Clinic
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Cancer Center
-
-
Missouri
-
Springfield, Missouri, United States, 65804
- St. John's Regional Health Center
-
Springfield, Missouri, United States, 65807
- Hulston Cancer Center at Cox Medical Center South
-
Springfield, Missouri, United States, 65804
- CCOP - Cancer Research for the Ozarks
-
-
Montana
-
Billings, Montana, United States, 59101
- CCOP - Montana Cancer Consortium
-
Billings, Montana, United States, 59101
- St. Vincent Healthcare Cancer Care Services
-
Billings, Montana, United States, 59107-7000
- Billings Clinic - Downtown
-
Billings, Montana, United States, 59102
- Hematology-Oncology Centers of the Northern Rockies - Billings
-
Bozeman, Montana, United States, 59715
- Bozeman Deaconess Cancer Center
-
Butte, Montana, United States, 59701
- St. James Healthcare Cancer Care
-
Great Falls, Montana, United States, 59405
- Sletten Cancer Institute at Benefis Healthcare
-
Helena, Montana, United States, 59601
- St. Peter's Hospital
-
Kalispell, Montana, United States, 59901
- Kalispell Regional Medical Center
-
Missoula, Montana, United States, 59807-7877
- Montana Cancer Specialists at Montana Cancer Center
-
Missoula, Montana, United States, 59807
- Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
-
-
North Dakota
-
Bismarck, North Dakota, United States, 58501
- Medcenter One Hospital Cancer Care Center
-
Bismarck, North Dakota, United States, 58501
- Mid Dakota Clinic, PC
-
Bismarck, North Dakota, United States, 58502
- St. Alexius Medical Center Cancer Center
-
Fargo, North Dakota, United States, 58122
- CCOP - MeritCare Hospital
-
Fargo, North Dakota, United States, 58102
- MeritCare Broadway
-
-
Ohio
-
Bowling Green, Ohio, United States, 43402
- Wood County Oncology Center
-
Dayton, Ohio, United States, 45405
- Grandview Hospital
-
Dayton, Ohio, United States, 45406
- Good Samaritan Hospital
-
Dayton, Ohio, United States, 45409
- David L. Rike Cancer Center at Miami Valley Hospital
-
Dayton, Ohio, United States, 45415
- Samaritan North Cancer Care Center
-
Dayton, Ohio, United States, 45420
- CCOP - Dayton
-
Elyria, Ohio, United States, 44035
- Community Cancer Center
-
Elyria, Ohio, United States, 44035
- Hematology Oncology Center
-
Findlay, Ohio, United States, 45840
- Blanchard Valley Medical Associates
-
Franklin, Ohio, United States, 45005-1066
- Middletown Regional Hospital
-
Greenville, Ohio, United States, 45331
- Wayne Hospital
-
Kettering, Ohio, United States, 45429
- Charles F. Kettering Memorial Hospital
-
Lima, Ohio, United States, 45804
- Lima Memorial Hospital
-
Maumee, Ohio, United States, 43537-1839
- Northwest Ohio Oncology Center
-
Oregon, Ohio, United States, 43616
- St. Charles Mercy Hospital
-
Oregon, Ohio, United States, 43616
- Toledo Clinic - Oregon
-
Sylvania, Ohio, United States, 43560
- Flower Hospital Cancer Center
-
Tiffin, Ohio, United States, 44883
- Mercy Hospital of Tiffin
-
Toledo, Ohio, United States, 43608
- St. Vincent Mercy Medical Center
-
Toledo, Ohio, United States, 43606
- Toledo Hospital
-
Toledo, Ohio, United States, 43614
- Medical University of Ohio Cancer Center
-
Toledo, Ohio, United States, 43617
- CCOP - Toledo Community Hospital
-
Toledo, Ohio, United States, 43623
- Toledo Clinic, Incorporated - Main Clinic
-
Toledo, Ohio, United States, 43623
- St. Anne Mercy Hospital
-
Troy, Ohio, United States, 45373-1300
- UVMC Cancer Care Center at Upper Valley Medical Center
-
Wauseon, Ohio, United States, 43567
- Fulton County Health Center
-
Xenia, Ohio, United States, 45385
- Ruth G. McMillan Cancer Center at Greene Memorial Hospital
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57117-5039
- Sanford Cancer Center at Sanford USD Medical Center
-
-
Virginia
-
Fredericksburg, Virginia, United States, 22401
- Fredericksburg Oncology, Incorporated
-
-
Wisconsin
-
Green Bay, Wisconsin, United States, 54307-3508
- St. Vincent Hospital Regional Cancer Center
-
Green Bay, Wisconsin, United States, 54301-3526
- Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
-
Green Bay, Wisconsin, United States, 54303
- Green Bay Oncology, Limited at St. Mary's Hospital
-
Green Bay, Wisconsin, United States, 54303
- St. Mary's Hospital Medical Center - Green Bay
-
Manitowoc, Wisconsin, United States, 54221-1450
- Holy Family Memorial Medical Center Cancer Care Center
-
Marinette, Wisconsin, United States, 54143
- Bay Area Cancer Care Center at Bay Area Medical Center
-
Oconto Falls, Wisconsin, United States, 54154
- Green Bay Oncology, Limited - Oconto Falls
-
Sheboygan, Wisconsin, United States, 53081
- St. Nicholas Hospital
-
Sturgeon Bay, Wisconsin, United States, 54235
- Green Bay Oncology, Limited - Sturgeon Bay
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Histological confirmation of metastatic adenocarcinoma, poorly differentiated non-small cell carcinoma, or poorly differentiated squamous carcinoma
- Adequate FFPE tissue or re-biopsy planned after registration but prior to treatment
- Measurable disease as defined; for patients having only lesions measuring at least 1 cm to =< 2 cm must use spiral computed tomography (CT) imaging for both pre- and post-treatment tumor assessments; disease that has received prior radiation (performed for palliative reasons) cannot be used for measurable disease
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Hemoglobin (Hgb) >= 9.0 g/dL
- Absolute neutrophil count (ANC) >= 1,500/uL
- Platelet count >= 100,000/uL
- Total bilirubin =< upper limits of normal (ULN); if liver metastases are present, total bilirubin =< 2 x ULN
- Aspartate aminotransferase (AST) =< 2.5 x ULN; if liver metastases are present, AST =< 5 x ULN
- Creatinine =< 1.25 x ULN; if > 1.25 x ULN calculated creatinine clearance must be >= 60 ml/min
- Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
- Provide informed written consent
- Willingness to return to NCCTG enrolling institution for follow-up
- Willingness to abstain from eating grapefruit or drinking grapefruit juice for the duration of the study
Exclusion Criteria
Any of the following:
- Pregnant women
- Nursing women
- Men or women of childbearing potential who are unwilling to employ adequate contraception; note: adequate contraception must be used throughout the trial and for 8 weeks after the last dose of RAD001, by both sexes
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
History of any of the following:
- Known to be human immunodeficiency virus (HIV) positive
- Known prior/current history of hepatitis related to hepatitis B or hepatitis C
Uncontrolled intercurrent illness including, but not limited to the following:
- Ongoing or active infection (acute or chronic)
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Cardiac arrhythmia
- Severely impaired lung function
- Uncontrolled diabetes as defined by fasting serum glucose > 1.5 x ULN (note: optimal glycemic control should be achieved before starting trial therapy)
- Liver disease such as cirrhosis or severe hepatic impairment
- Psychiatric illness/social situations that would limit compliance with study requirements
- Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm =< 4 weeks prior to registration
- Other active malignancy =< 5 years prior to registration; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: if there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer
- Untreated brain metastases; NOTE: patients with treated, stable brain metastases for at least 12 weeks prior to study entry are eligible for enrollment
- Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)
- Active, bleeding diathesis
- Receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; topical or inhaled corticosteroids are allowed
- Currently on enzyme inducing anti-convulsants (EIACs) or other strong inducers or strong inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)
- Current use of warfarin (Coumadin); EXCEPTION: current use of low-molecular weight heparin is allowed
- Known to be HIV positive
- Inoculated with live attenuated vaccines =< 2 weeks prior to registration; note: close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow fever, varicella and TY21a typhoid vaccines
- =< 4 weeks from major surgery; note: for this study, diagnostic laparoscopy (without other intervention) and/or biopsies (needle aspirate, core biopsy, open biopsy, etc.) are not considered major surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (carboplatin, paclitaxel, and everolimus)
Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1.
Patients also receive everolimus PO QD on days 1, 8, and 15.
Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
|
Given IV
Given IV
Given PO
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Confirmed Tumor Responses
Time Frame: First 6 Cycles of treatment (an average of 6 months)
|
Confirmed tumor response was defined to be either a complete response (CR) or partial response (PR) noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria:
|
First 6 Cycles of treatment (an average of 6 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: Time from registration to death or last follow-up (up to 3 years)
|
Overall survival was defined as the time from study enrollment to the time of death from any cause or last follow-up.
|
Time from registration to death or last follow-up (up to 3 years)
|
Progression-free Survival
Time Frame: Time from registration to the disease progression or death (up to 3 years)
|
The progression-free survival (PFS) was defined as the time from date of registration to the documentation of disease progression or death as a result of any cause, whichever comes first.
|
Time from registration to the disease progression or death (up to 3 years)
|
Duration of Response
Time Frame: Up to 3 years
|
Duration of response was defined for all evaluable participants who have achieved an objective response as the date at which the participant's objective status is first noted to be either CR or PR to the date progression is documented.
|
Up to 3 years
|
Time to Treatment Failure
Time Frame: Up to 3 years
|
Time to treatment failure was defined to be the time from the date of registration to the date at which the participant is removed from treatment due to progression, adverse events, or refusal.
|
Up to 3 years
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Matthew P. Goetz, MD, Mayo Clinic
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplastic Processes
- Neoplasm Metastasis
- Carcinoma
- Neoplasms, Unknown Primary
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Carboplatin
- Paclitaxel
- Everolimus
Other Study ID Numbers
- NCCTG-N0871
- NCI-2011-01926 (Registry Identifier: CTRP (Clinical Trials Reporting System))
- CDR0000643361 (Registry Identifier: PDQ (Physician Data Query))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma of Unknown Primary Origin
-
Rigshospitalet, DenmarkThe Novo Nordic FoundationCompletedUnknown Primary Cancer | Cancer of Unknown Primary Site | Unknown Primary, Squamous Cell CarcinomaDenmark
-
Repos PharmaUppsala University; Uppsala University HospitalTerminatedCancer of the Gastrointestinal Tract | Cancer of Unknown OriginSweden
-
AHS Cancer Control AlbertaTom Baker Cancer CentreActive, not recruitingCarcinoma of Unknown PrimaryCanada
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedCarcinoma of Unknown PrimaryUnited States
-
University of Michigan Rogel Cancer CenterEli Lilly and CompanyTerminatedCarcinoma of Unknown PrimaryUnited States
-
European Organisation for Research and Treatment...NCIC Clinical Trials Group; Radiation Therapy Oncology Group; Danish Head and...CompletedCarcinoma of Unknown PrimaryUnited States, Canada, Switzerland, Belgium, Netherlands, Denmark
-
Samsung Medical CenterUnknownCarcinoma of Unknown PrimaryKorea, Republic of
-
OnxeoSpectrum Pharmaceuticals, IncCompletedCarcinoma of Unknown PrimaryUnited States, Germany, France, Denmark
-
University of Medicine and Dentistry of New JerseyNational Cancer Institute (NCI)WithdrawnCarcinoma of Unknown PrimaryUnited States
-
Academisch Ziekenhuis MaastrichtUnknownCarcinoma of Unknown PrimaryNetherlands
Clinical Trials on paclitaxel
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast CarcinomaUnited States
-
Hutchison Medipharma LimitedSun Yat-sen UniversityActive, not recruitingAdvanced Gastric CancerChina
-
Anne NoonanNational Cancer Institute (NCI)RecruitingStage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic AdenocarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI); Celgene CorporationCompletedRecurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung CancerUnited States
-
Shengjing HospitalRecruiting
-
CTI BioPharmaTerminatedNSCLCUnited States, Canada, Bulgaria, Romania, Russian Federation, Ukraine, Mexico, Argentina, Hungary, Poland, United Kingdom
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
CTI BioPharmaTerminated
-
Novartis PharmaceuticalsCompletedMetastatic or Locally Advanced Solid TumorsNetherlands, Spain, Germany, Switzerland, Belgium